Development of AX-5006 a Small Molecule Inhibitor of CsgA Aggregation As a Potential Disease Modifying Treatment for Parkinson’s Disease
Time: 12:30 pm
day: Conference Day 1 Track A AM 1
Details:
- Understanding the role of the microbiome in Parkinson’s Disease
- Outlining the rationale for targeting CsgA as a therapeutic for Parkinson’s Disease
- Revealing the preclinical efficacy, pharmacokinetics, and tolerability profile of AX-5006
